Do elderly cancer patients achieve an adequate dose intensity in common clinical practice?

Oncology

Volumn 71, Issue 5-6, 2007, Pages 382-387

  Luciani, A ^a   Marussi, D ^a   Ascione, G ^a   Caldiera, S ^a   Ferrari, D ^a   Oldani, S ^a   Uziel, L ^a   Zonato, S ^a   Foa, P ^a  

^a SAN PAOLO HOSPITAL   (Italy)

Author keywords

Chemotherapy; Dose intensity; Elderly cancer patients

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; GEMCITABINE; NAVELBINE;

ADULT; AGED; ARTICLE; BILIARY TRACT CANCER; BLOOD TOXICITY; BREAST CANCER; CLINICAL PRACTICE; COLORECTAL CANCER; COMORBIDITY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; ELDERLY CARE; ESOPHAGUS CANCER; EXPERIENCE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OPTIMAL DRUG DOSE; OVARY CANCER; PANCREAS CANCER; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOLID TUMOR; STOMACH CANCER;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; NEOPLASMS; PATIENT SELECTION; RETROSPECTIVE STUDIES;

EID: 35348876306     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000108386     Document Type: Article

References (50)

1. Balducci L, Ershler WB: Cancer and ageing: a nexus at several levels. Nat Rev Cancer 2005;5:655-662.
2. Goldin A, Humphreys SR, Mantel N, et al: Modification of treatment of schedules in the management of advanced mouse leukemia with amethopterin. J Natl Cancer Inst 1956;17:203-212.
3. Goldin A, Humphreys SR, Venditti JM, et al: Growth studies on sarcoma 37 in mice. J Natl Cancer Inst 1956;16:1207-1220.
4. Norton L, Simon R: The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986;70:163-169.
5. Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281-1288.
6. Sculier JP, Lafitte JJ, Berghmans T, et al: A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer. Ann Oncol 2004;15:399-409.
7. Jacobson JO, Grossbard M, Shulman LN, et al: CHOP chemotherapy with preemptive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma: a dose-intensity analysis. Clin Lymphoma 2000;1:211-217; discussion 218.
8. Jost LM, Widmer L, Honegger HP, et al: Index of pretreatment intensity predicts outcome of high-dose chemotherapy and autologous progenitor cell transplantation in chemosensitive relapse of Hodgkin's disease. Ann Oncol 1997;8:785-790.
9. 2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. Ann Oncol 1997;8:155-162.
10. Woll PJ, Hodgetts J, Lomax L, et al: Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol 1995;13:652-659.
11. Miles DW, Fogarty O, Ash CM, et al: Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. J Clin Oncol 1994;12:77-82.
12. Marsland TA, Garfield DH, Khan MM, et al: Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two phase II, multicenter trials. Lung Cancer 2005;47:111-120.
13. Tibaldi C, Ricci S, Russo F, et al: Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the 'polmone toscano group' (POLTO). Lung Cancer 2005;48:121-127.
14. Massacesi C, Marcucci F, Boccetti T, et al: Low dose-intensity docetaxel in the treatment of pre-treated elderly patients with metastatic breast cancer. J Exp Clin Cancer Res 2005;24:43-48.
15. Kim JH, Oh DY, Kim YJ, et al: Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer. J Korean Med Sci 2005;20:806-810.
16. Lyman GH, Dale DC, Crawford J: Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21:4524-4531.
17. Miller MD, Paradis CF, Houck PR, et al: Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 1992;41:237-248.
18. Trotti A, Colevas AD, Setser A, et al: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-181.
19. Hryniuk WM, Goodyear M: The calculation of received dose intensity. J Clin Oncol 1990;8:1935-1937.
20. Skipper H: Data and analysis having to do with the influence of dose intensity and duration of treatment (single drugs and combination) on lethal toxicity and the therapeutic response of experimental neoplasm. Birmingham, Southern Research Institute, 1986, Booklet 3, and 1987, Booklets 2-13.
21. Gregory SA, Trumper L: Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes? Ann Oncol 2005;16:1413-1424.
22. Minor DR, Madland MT, Kashani-Sabet M, et al: A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity. Cancer Biother Radiopharm 2005;20:479-486.
23. Patel K, Anthoney DA, Crellin AM, et al: Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher doseintensity in adjuvant chemotherapy after colorectal cancer resection. Ann Oncol 2004;15:568-573.
24. Keyes KA, Albella B, LoRusso PM, et al: Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond. Clin Cancer Res 2000;6:2474-2481.
25. De Placido S, Lauria R, Carlomagno C, et al: The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer. Int J Oncol 1999;15:339-346.
26. Klasa RJ, Murray N, Coldman AJ: Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 1991;9:499-508.
27. Schmitz N, Kloess M, Reiser M, et al: Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma. Cancer 2006;106:136-145.
28. Portlock CS: Dose density and dose intensity: where does CHOP go from here? Ann Oncol 2002;13:1329-1330.
29. Balzarotti M, Spina M, Sarina B, et al: Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide. Ann Oncol 2002;13:1341-1346.
30. Surbone A, Kagawa-Singer M, Terret C, et al: The illness trajectory of elderly cancer patients across cultures: SIOG position paper. Ann Oncol 2007;18:633-638.
31. Crawford J: The importance of chemotherapy dose intensity in lung cancer. Semin Oncol 2004;31:25-31.
32. Tjan-Heijnen VCG, Wagener DJT, Postmus PE: An analysis of chemotherapy dose and dose-intensity in small-cell lung cancer: lessons to be drawn. Ann Oncol 2002;13:1519-1530.
33. Bergh J: Dose intensity in patients with metastatic breast cancer - time for novel thoughts? Ann Oncol 1997;8:109-110.
34. Giovanazzi-Bannon S, Rademaker A, Lai G, et al: Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study. J Clin Oncol 1994;12:2447-2452.
35. Rikkert MG, Diepstraten AM: Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions. Cancer 1999;85:1210-1211.
36. Repetto L, Venturino A, Vercelli M, et al: Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions. Cancer 1998;82:760-765.
37. Shayne M, Crawford J, Dale DC, et al: Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 2006;100:255-262.
38. Lyman GH, Dale DC, Friedberg J, et al: Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004;22:4302-4311.
39. 2 plus low-dose folinic acid for 24 weeks as adjuvant treatment for colorectal cancer: assessment of toxicity and delivery. Clin Oncol (R Coll Radiol) 2006;18:649-657.
40. Firat S, Pleister A, Byhardt RW, et al: Age is independent of comorbidity influencing patient selection for combined modality therapy for treatment of stage III nonsmall cell lung cancer (NSCLC). Am J Clin Oncol 2006;29:252-257.
41. Gonlugur TE, Gonlugur U: Comorbidity as a prognostic factor in small cell lung cancer. Tumori 2006;92:423-428.
42. Firat S, Bousamra M, Gore E, et al: Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;52:1047-1057.
43. Firat S, Byhardt RW, Gore E: Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2002;54:357-364.
44. Perrone F, Di Maio M, Gallo C, et al: Outcome of patients with a performance status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES). J Clin Oncol 2004;22:5018-5020; 5020-5021.
45. Lee D: Benefit of active treatment in non-small-cell lung cancer in elderly patients and patients with poor performance status. Clin Lung Cancer 2003;5:86-89.
46. Gronlund B, Hogdall C, Hansen HH, et al: Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer 2002;94:1961-1967.
47. Gridelli C, Hainsworth J: Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLC. Lung Cancer 2002;38(suppl 4):37-41.
48. Repetto L, Fratino L, Audisio RA, et al: Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002;20:494-502.
49. Dobie SA, Baldwin LM, Dominitz JA, et al: Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst 2006;98:610-619.
50. Grann VR, Muggia FM: Completion rates of adjuvant chemotherapy for colon cancer: a historical perspective. J Natl Cancer Inst 2006;98:570-571.